225 related articles for article (PubMed ID: 10895850)
21. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
Hershon KS; Hershon PM
Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
[TBL] [Abstract][Full Text] [Related]
22. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.
Kuzuya T; Iwamoto Y; Kosaka K; Takebe K; Yamanouchi T; Kasuga M; Kajinuma H; Akanuma Y; Yoshida S; Shigeta Y
Diabetes Res Clin Pract; 1991 Mar; 11(3):147-53. PubMed ID: 2036936
[TBL] [Abstract][Full Text] [Related]
23. The use of insulin secretagogues in the treatment of type 2 diabetes.
Luna B; Hughes AT; Feinglos MN
Prim Care; 1999 Dec; 26(4):895-915. PubMed ID: 10523467
[TBL] [Abstract][Full Text] [Related]
24. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.
Moses RG; Gomis R; Frandsen KB; Schlienger JL; Dedov I
Diabetes Care; 2001 Jan; 24(1):11-5. PubMed ID: 11194214
[TBL] [Abstract][Full Text] [Related]
25. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
[TBL] [Abstract][Full Text] [Related]
26. Repaglinide versus glyburide: a one-year comparison trial.
Marbury T; Huang WC; Strange P; Lebovitz H
Diabetes Res Clin Pract; 1999 Mar; 43(3):155-66. PubMed ID: 10369424
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
Nishimura A; Usui S; Kumashiro N; Uchino H; Yamato A; Yasuda D; Nagasawa K; Okubo M; Mori Y; Hirose T
Endocr J; 2016 Dec; 63(12):1087-1098. PubMed ID: 27647480
[TBL] [Abstract][Full Text] [Related]
28. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
29. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.
Strowig SM; Avilés-Santa ML; Raskin P
Diabetes Care; 2002 Oct; 25(10):1691-8. PubMed ID: 12351463
[TBL] [Abstract][Full Text] [Related]
30. Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group.
Buysschaert M; Bobbioni E; Starkie M; Frith L
Diabet Med; 1999 Feb; 16(2):147-53. PubMed ID: 10229309
[TBL] [Abstract][Full Text] [Related]
31. Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients.
Murase Y; Wakasugi T; Yagi K; Mabuchi H
Diabetes Care; 2000 Jan; 23(1):131-2. PubMed ID: 10857989
[No Abstract] [Full Text] [Related]
32. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
Maruyama S; Yanagisawa K; Kanamuro R; Teno S; Iwamoto Y
Diabetes Res Clin Pract; 2001 Sep; 53(3):161-4. PubMed ID: 11483231
[TBL] [Abstract][Full Text] [Related]
33. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.
Buse JB; Gumbiner B; Mathias NP; Nelson DM; Faja BW; Whitcomb RW
Diabetes Care; 1998 Sep; 21(9):1455-61. PubMed ID: 9727891
[TBL] [Abstract][Full Text] [Related]
34. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
Xu W; Mu Y; Zhao J; Zhu D; Ji Q; Zhou Z; Yao B; Mao A; Engel SS; Zhao B; Bi Y; Zeng L; Ran X; Lu J; Ji L; Yang W; Jia W; Weng J
Sci China Life Sci; 2017 Mar; 60(3):225-238. PubMed ID: 28271251
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
37. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
Blonde L; Sandberg MI; Guthrie RD
Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
[No Abstract] [Full Text] [Related]
38. Repaglinide in combination therapy with metformin in Type 2 diabetes.
Moses R
Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S136-9. PubMed ID: 10522839
[TBL] [Abstract][Full Text] [Related]
39. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
[No Abstract] [Full Text] [Related]
40. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]